Stock 6562 UBI PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company UBI Pharma Inc.

Equities

6562

TW0006562002

Pharmaceuticals

End-of-day quote Taipei Exchange
Other stock markets
 18:00:00 2024-04-25 EDT 		5-day change 1st Jan Change
13.9 TWD -12.30% Intraday chart for UBI Pharma Inc. -27.03% -59.88%
04-18 UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Business Summary

UBI Pharma Inc is a Taiwan-based company mainly engaged in development and manufacturing of protein drugs and special dosage-form drugs. The Company is engaged in research and development, manufacturing and sales of protein drugs and special dosage-form drugs, contract manufacturing of pharmaceuticals, and provision of contract research services. The protein drug product line includes erythropoietin (UB-851) biosimilar drugs, innovative long-acting erythropoietin (UB-852), innovative long-acting granular ball community stimulating hormone (UB-853), and others used to treat anemia, neutropenia. The small molecule new drug product line includes B-Raf kinase inhibitor (UB-941) for the treatment of melanoma. The special scientific name drug product line includes tablets Olanzapine and Nevirapin for the treatment of schizophrenia and AIDS, and injections Granisetronl and Meropenen for the treatment of bacterial infections. It sells products in the domestic market and overseas markets.

Sales per Business

TWD in Million2022Weight2023Weight Delta
Pharmaceutical Commissioned Manufacturing
68.2 %
410 64.7 % 442 68.2 % +7.77%
Technology Services
18.2 %
113 17.9 % 118 18.2 % +4.13%
Sales
11.1 %
101 16.0 % 72 11.1 % -28.85%
Other
2.5 %
9 1.4 % 16 2.5 % +85.65%

Sales per region

TWD in Million2022Weight2023Weight Delta
Other
52.7 %
343 54.1 % 342 52.7 % -0.37%
Taiwan
47.3 %
291 45.9 % 307 47.3 % +5.52%

Managers

Managers TitleAgeSince
Chi Hsiang Chen CEO
 Chief Executive Officer - 18-10-02
Meng Han Hsu DFI
 Director of Finance/CFO - 16-04-10
Ying Yun Fan ADM
 Chief Administrative Officer - 15-02-28
Yan Ning Kuo BRD
 Director/Board Member - 20-06-29
Wen Chun Peng PRN
 Corporate Officer/Principal - 15-02-28
Pai Feng Wu PRN
 Corporate Officer/Principal - 14-07-30

Members of the board

Members of the board TitleAgeSince
Chi Hsiang Chen CEO
 Chief Executive Officer - 18-10-02
Ping-Ho Yan BRD
 Director/Board Member - -
Pai Feng Wu PRN
 Corporate Officer/Principal - 14-07-30
Wen Chun Peng PRN
 Corporate Officer/Principal - 15-02-28
Ying Yun Fan ADM
 Chief Administrative Officer - 15-02-28
Shih Chia Lin BRD
 Director/Board Member - -
Yan Ning Kuo BRD
 Director/Board Member - 20-06-29
Yao Hui Wei BRD
 Director/Board Member - 20-06-29
Chi Kang Lu BRD
 Director/Board Member - -
Chen Lin Hsu BRD
 Director/Board Member - -

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 118,190,200 32,822,713 ( 27.77 %) 70,000 ( 0.0592 %) 27.77 %

Company contact information

UBI Pharma Inc.

45 Guangfu North Road Hukou Township

303 51, Hsinchu

+

http://www.ubi-pharma.com
address UBI Pharma Inc.(6562)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sales per region

Sector Other Pharmaceuticals

1st Jan change Capi.
UBI PHARMA INC. Stock UBI Pharma Inc.
-59.88% 50.36M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 6562 Stock
  4. Company UBI Pharma Inc.